Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00128440 · ClinicalTrials.gov registry record · Phase 2
High Dose Trial in COPD
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT00128440 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 78 participants.
The verdict
NCT00128440, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
The primary objective of this study was to compare the efficacy and safety of 200 μg and 400 μg of BEA 2180 BR to tiotropium 5 μg and placebo when each was delivered by the Respimat® Inhaler once daily for four weeks in patients with COPD.
Interventions
- DRUG tiotropium
- DRUG BEA 2180 BR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00128440
The ClinicalTrials.gov registry entry for NCT00128440 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tiotropium is the first listed.
NCT00128440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00128440 about?
NCT00128440 is a clinical study titled "High Dose Trial in COPD". The primary objective of this study was to compare the efficacy and safety of 200 μg and 400 μg of BEA 2180 BR to tiotropium 5 μg and placebo when each was delivered by the Respimat® Inhaler once daily for four weeks in patients with COPD.
What is the current status of trial NCT00128440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2005-08.
What interventions are being tested in trial NCT00128440?
The interventions under investigation include: tiotropium (DRUG), BEA 2180 BR (DRUG).
Who is sponsoring clinical trial NCT00128440?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.